Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclosporine for COVID-19 Non-ICU Inpatients
NCT04492891Phase 2Completed
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in coronavirus disease 2019 (COVID-19) comparing Cyclosporine + SOC with Standard of Care (2 arms). Primary endpoint: World Health Organization COVID-19 Clinical Severity Scale at Day 14. Started Nov 2020; status: completed.
02
Drugs
cyclosporine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04492891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04492891.